Sagimet Biosciences Inc. (SGMT)
NASDAQ: SGMT · Real-Time Price · USD
8.75
+0.63 (7.76%)
At close: Apr 28, 2026, 4:00 PM EDT
8.79
+0.04 (0.46%)
After-hours: Apr 28, 2026, 7:59 PM EDT
Sagimet Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
16
Market Cap
285.12M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MacroGenics | 149.50M |
| Karyopharm Therapeutics | 146.07M |
| Precision BioSciences | 34.26M |
| Tonix Pharmaceuticals Holding | 13.11M |
| Whitehawk Therapeutics | 7.15M |
| Korro Bio | 6.39M |
| Cartesian Therapeutics | 2.80M |
SGMT News
- 1 day ago - Why Is Sagimet Biosciences Stock Trading Higher On Monday? - Benzinga
- 1 day ago - Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock - GlobeNewsWire
- 1 day ago - Sagimet Biosciences Provides Strategic and Corporate Updates - GlobeNewsWire
- 8 days ago - Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer - GlobeNewsWire
- 22 days ago - Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 7 weeks ago - Sagimet Biosciences Transcript: Leerink Global Healthcare Conference 2026 - Transcripts
- 2 months ago - Sagimet Biosciences Transcript: TD Cowen 46th Annual Health Care Conference - Transcripts